Visual of mutations

Focusing on function to mine cancer genome data

Apr 17, 2018

CCR scientists have devised a strategy to sift through the tens of thousands of mutations in cancer genome data to find mutations that actually drive the disease. They have used the method to discover that the JNK signaling pathway, which in different contexts can either spur cancerous growth or rein it in, acts as a tumor suppressor in gastric cancers.  Read more...

Subgroups of DLBCL

Study led by Louis Staudt revises molecular classification for most common type of lymphoma

Apr 13, 2018

Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma. Though potentially curable, treatment does not eliminate the disease for all patients. A new study led by Louis Staudt, M.D., Co-Chief of the Lymphoid Malignancies Branch, identified genetic subtypes of DLBCL that could help explain why some patients respond to treatment whereas others do not.  Read more...

Study led by Louis Staudt revises molecular classification for most common type of lymphoma
PC3 prostate cancer cells

Imaging technique predicts efficacy of targeting prostate tumor metabolism in mice

Apr 10, 2018

Disrupting glycolysis, a metabolic process tumors often rely on to feed their growth by partially breaking down sugars and not requiring oxygen, has emerged as a promising approach to treating metastatic prostate cancer in a study by Center for Cancer Research investigators.  Read more...

kidney tissue

Study reveals potentially prognostic gene, metabolism changes in kidney cancers

Apr 5, 2018

The Cancer Genome Atlas Research Network investigators, including CCR scientists, identified genetic and metabolic pathway changes linked to reduced survival of patients within and across subtypes of renal cell carcinoma (RCC), a type of kidney cancer. The study, published April 5, 2018, in Cell Reports, is part of The Cancer Genome Atlas (TCGA) Program, a joint effort of the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI). Read more...

Skin lesion of lupus patient

New study shows normally helpful natural bacteria may also trigger lupus

Mar 28, 2018

CCR scientists have discovered that a protein produced by bacteria that naturally inhabit our bodies may trigger the autoimmune disease lupus. The results of the study could unveil an entirely new set of drug targets for treating lupus and other autoimmune diseases. Read more…

iPSC-derived thymic emigrants

Stem-cell technology rejuvenates cancer-fighting cells used in immunotherapy

Mar 20, 2018

Using stem-cell technology and a three-dimensional culture system, CCR scientists turn back the clock on aging anti-cancer immune cells. Read more...

White blood cells

Potential cancer immunotherapy drug shows promise against HIV

Mar 19, 2018

An immunotherapy currently being tested in a clinical trial as a treatment for metastatic cancer has now shown potential in an animal study to reduce recalcitrant pools of SHIV, a laboratory-designed virus used to study human immunodeficiency virus (HIV) infection. The study, published online February 23 in PLoS Pathogens, is the result of a collaborative effort by CCR, the National Institute of Allergy and Infectious Diseases and the Frederick National Laboratory for Cancer Research. Read more…

HIV infected T cell

Promising drug target could restore immune system’s ability to fight HIV

Feb 9, 2018

Scientists in NCI’s Center for Cancer Research have identified a new target for drugs that could help people who are HIV-positive eliminate recalcitrant pools of the virus. The research findings were published January 5 in Science. Read more…

Cartoon illustrating how SLFN11acts like an alarm clock against abnormal DNA replication in a DNA-damaged cell

Study characterizes how DNA-damaging anti-cancer drugs kill cancer cells

Feb 2, 2018

Patients whose cancer cells express the SLFN11 protein are more likely to respond to DNA-damaging anti-cancer drugs than those whose cancer cells don’t express SLFN11. In a new study, Center for Cancer Research investigators show how these drugs recruit SLFN11 to block replication and kill cancer cells. Read more…

Eye

Scientists repurpose HPV vaccine technology to fight eye cancer

Jan 24, 2018

Uveal melanoma is a rare eye cancer that affects about 1,600 people in the United States. A study by scientists in the Center for Cancer Research and Aura Biosciences, Cambridge, Mass., published December 14, 2017, in Molecular Cancer Therapeutics, provides new hope for the early treatment of uveal melanoma. Read more…

Pages